BYSI (BeyondSpring Inc) Dhuwit awis perusahaan

Logo grafis beyondspringpharma.com (BYSI)

BeyondSpring Inc. (BYSI) generates revenue through the promotion of Plinabulin for the treatment of lung cancer and neutropenia. The cash flow trend on the GURU.Markets chart, where 0.00 represents the current metric level, confirms a dependency on procurement by clinics and insurance funds. However, an acute need for capital to fund new trials and previous FDA rejections create significant risks.

BYSI - Sisa dhuwit perusahaan BeyondSpring, Inc. ing rentang 04.07.2022 - 20.11.2026

Rincian metrik keuangan lan pasar BeyondSpring (BYSI)

Analisis komprehensif perusahaan:BYSI BeyondSpring Pharma
Produk mawa merek beyondspringpharma.com

BeyondSpring Inc. is currently focusing on strengthening its position within the oncology sector amid a pragmatic approach from investors. The liquid assets metric quantifies the capital available for operations, allowing the cash reserve trend to determine either a fundamental floor or the risk of resource stagnation, where excess cash loses value without effective reinvestment into business development.